News Quantified

FULC – fulcrum therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Fulcrum Therapeutics (NASDAQ:FULC) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $20.00 price target on the stock.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study [Yahoo! Finance]

Fulcrum Therapeutics (NASDAQ:FULC) was given a new $18.00 price target on by analysts at Truist Financial Corporation.

-5.6%

MISS

-0.3%

BEAT

89.6%

BEAT

0.0%

MISS

JPMorgan Chase & Co.

Form 8-K Fulcrum Therapeutics, For: Jan 12

Form 4 Fulcrum Therapeutics, For: Jan 02 Filed by: Gould Robert J

Form 4 Fulcrum Therapeutics, For: Dec 15 Filed by: Oltmans Curtis Gale

Form 144 Fulcrum Therapeutics, Filed by: Oltmans Curtis Gale

Form 8-K Fulcrum Therapeutics, For: Dec 10

Top News Gainers

11/19 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 25.0%

2/14 Form SC 13G Fulcrum Therapeutics, Filed by: GLAXOSMITHKLINE PLC 21.7%

8/19 Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD 21.2%

12/17 Hedge Funds Have Never Been This Bullish On Fulcrum Therapeutics, Inc. (FULC) [Yahoo! Finance News] 15.4%

10/30 Fulcrum Therapeutics (NASDAQ: FULC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 15.1%

2/26 Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD) 13.2%

2/20 Fulcrum Therapeutics to Participate in Upcoming Investor Conferences 10.3%

8/26 Form 8-K Fulcrum Therapeutics, For: Aug 26 8.8%

4/29 Form DEF 14A Fulcrum Therapeutics, For: Jun 11 8.6%

4/16 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 6.6%

Top News Decliners

8/1 Fulcrum Therapeutics to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference -12.9%

8/14 Form SEC STAFF LETTER Fulcrum Therapeutics, -10.3%

3/10 Fulcrum Therapeutics, Inc. (FULC) Q4 2019 Earnings Call Transcript [The Motley Fool] -9.2%

8/15 Fulcrum Therapeutics (NASDAQ: FULC) had its "outperform" rating re-affirmed by analysts at Svb Leerink Llc. -8.8%

1/21 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.6%

7/17 Form 3 Fulcrum Therapeutics, For: Jul 17 Filed by: Third Rock Ventures GP IV, L.P. -6.9%

4/13 Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease -6.3%

7/18 Form 4 Fulcrum Therapeutics, For: Jul 18 Filed by: Cadavid Diego -6.3%

4/17 Fulcrum Therapeutics (NASDAQ: FULC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.1%

3/5 Form 10-K Fulcrum Therapeutics, For: Dec 31 -4.9%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day